This is unpublished

Inflammatory Bowel Disease Clinical Trials

Additional information regarding study design, inclusion criteria, and exclusion criteria is available on ClinicalTrials.gov using the protocol number and sponsor information.

Actively Enrolling / Open  - Studies that are currently open and recruiting participants

  • A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease (Takeda Development Center Americas, Inc.: Protocol TAK-279-CD-2001)
  • A Phase 2, Open-Label Extension Trial to Evaluate the Long-term Safety and Tolerability of Oral Zasocitinib (TAK-279) in Participants with Moderately to Severely Active Ulcerative Colitis and Moderately to Severely Active Crohn’s Disease (Takeda Development Center Americas, Inc.:  Protocol TAK-279-IBD-2001)
  • A phase 2b, multicenter, double-blind, placebo-controlled, study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of obefazimod in subjects with moderately to severely active Crohn’s disease (Abivax: Protocol ABX464-202)
  • Phase IIa, sequential cohort, open-label, multi-center clinical trial to evaluate the efficacy, safety, and tolerability of intravenous induction and subcutaneous maintenance treatment with BI 3032950 in patients with moderate to severe ulcerative colitis  (Boehringer Ingelheim Pharma GmbH & Co. KG:  Protocol 1486-0006)
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease (Merck Sharp & Dohme LLC:  Protocol 008-03)
  • Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis (Spyre Therapeutics, Inc.:  Protocol SPY123-201)
  • A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease (Spyre Therapeutics, Inc.:  Protocol SPY123-202)
  • A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects with Moderate to Severe Treatment-Refractory Crohn’s Disease  (Tr1X, Inc.:  Protocol TRX103-02)
  • Long-term Follow-up of Subjects Who Received TRX103 in a Clinical Study Sponsored by Tr1X, Inc.  (Tr1X, Inc.:  Protocol TRX103-LTFU)

Opening Soon - Studies that are expected to open for enrollment in the near future

  • A Phase 2b, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Clinical Study to Evaluate the Efficacy and Safety of ATH-063 Induction Therapy in Patients with Biologic Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) (Athos Therapeutics, Inc.:  Protocol ATH-002-000)
  • A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of XmAb942 in Participants with Moderate-To-Severe Active Ulcerative Colitis (Xencor Inc.: Protocol XmAb942-01 (G942-101))
  • A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (Sanofi US. Services Inc.:  Protocol EFC18325)
  • A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis (Sanofi US. Services Inc.:  Protocol EFC18359)
  • A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease  (Sanofi US. Services Inc.:  Protocol EFC18326)
  • A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease (Sanofi US. Services Inc.: Protocol EFC18327)

Under Negotiation, with an anticipated timeline of approximately 2-3 months before activation

  • A phase III, multicenter, double-blind, placebo-controlled study to assess the efficacy and safety of induction therapy with ro7790121 in patients with moderately to severely active Crohn’s disease (F. Hoffmann-La Roche Ltd:  Protocol GA45332)
  • A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease (Janssen Research & Development:  Protocol CNTO1959CRD3009)
  • Multicenter, placebo-controlled randomised, double blind, Phase 2 study to assess efficacy, safety, tolerability and pharmacokinetics of RXC008 in participants with strictures due to Crohn’s disease following treatment with orally administered RXC008 (Redx Pharma Ltd:  Protocol RXC008-0002)